Changes in management of Karo Bio AB

STOCKHOLM, September 30, 2011 - Karo Bio AB (publ) today announced that Chief Financial Officer, Erika Söderberg Johnson, leaves her position.

Karo Bio’s CFO Erika Söderberg Johnson will leave Karo Bio at the end of the year. She has been CFO at Karo Bio since 2007. The search for a new CFO has been initiated.

For further information please contact:
Per Bengtsson, acting CEO and President
Mobile: +46 734 474 128

About Karo Bio

Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas cardiovascular and metabolic diseases, neuropsychiatry, inflammation, autoimmune diseases, cancer and women’s health. An important foundation for the company’s activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 70 employees and is listed on NASDAQ OMX Stockholm.

This information is such that Karo Bio is required to disclose under the Swedish Securities Market Act. The information was disclosed on September 30, 2011, 13:00 CET.

This press release is also available online at www.karobio.se and www.newsroom.cision.com

About Us

Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.

Subscribe

Documents & Links